Principal Financial Group Inc. Sells 2,876 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Principal Financial Group Inc. decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report) by 12.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 19,629 shares of the biopharmaceutical company’s stock after selling 2,876 shares during the quarter. Principal Financial Group Inc.’s holdings in Alnylam Pharmaceuticals were worth $3,757,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Quent Capital LLC boosted its stake in Alnylam Pharmaceuticals by 246.0% during the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 123 shares during the last quarter. Anchor Investment Management LLC bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $38,000. GAMMA Investing LLC bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $52,000. Lindbrook Capital LLC lifted its stake in Alnylam Pharmaceuticals by 37.2% in the fourth quarter. Lindbrook Capital LLC now owns 369 shares of the biopharmaceutical company’s stock valued at $71,000 after buying an additional 100 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $71,000. Institutional investors own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

ALNY has been the topic of a number of research reports. Citigroup cut their price target on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating on the stock in a research note on Friday, February 16th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $235.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. Needham & Company LLC reissued a “buy” rating and issued a $200.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Thursday, May 2nd. Wells Fargo & Company cut their price objective on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating on the stock in a research report on Friday, February 16th. Finally, Wolfe Research assumed coverage on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 15th. They issued a “peer perform” rating on the stock. Seven equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $216.19.

Check Out Our Latest Report on ALNY

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Amy W. Schulman sold 21,700 shares of the company’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total value of $3,224,620.00. Following the transaction, the director now directly owns 8,436 shares in the company, valued at $1,253,589.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $148.43 on Friday. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $218.88. The company has a market cap of $18.77 billion, a P/E ratio of -55.88 and a beta of 0.41. The firm’s fifty day moving average price is $149.46 and its two-hundred day moving average price is $163.61.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.23. The company had revenue of $494.33 million during the quarter, compared to analyst estimates of $428.01 million. During the same quarter in the prior year, the firm earned ($1.40) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 54.8% on a year-over-year basis. As a group, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -3.77 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

(Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Recommended Stories

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.